170 Results for "

Pain model

" in MedChemExpress (MCE) Product Catalog:
Products (170)

170 Results for "Pain model" in MCE Product Catalog:

25
25 Publications Verification
Cat. No.: HY-153808
CAS No.: 9007-81-2
Research Areas:  

Inflammation/Immunology

Complete Freund's adjuvant (CFA) is an immunoadjuvant emulsified with antigen by its discoverer Jules T. Freund to enhance an animal's immune response to an antigen. Complete Freund's adjuvant (CFA) is also an inducer of the Th1 immune response and a ligand of TLRs. Complete Freund's adjuvant (CFA) contains heat-killed inactive tuberculosis bacilli and consists of a paraffin oil-in-water emulsion. Complete Freund's adjuvant (CFA) stimulates a strong and durable immune response and can be used to induce persistent inflammatory pain models in mice, experimental autoimmune myocarditis (EAM) models, and more. Incomplete Freund's adjuvant (IFA) (HY-153808A) is another type of Freund's Adjuvant that stimulates a weaker immune response .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-N2258
CAS No.: 14941-08-3
Poncirin is isolated from Poncirus trifoliata with anti-inflammory activites. Poncirin significantly reduces mechanical hyperalgesia and allodynia in Complete Freund’s Adjuvant (CFA)-induced inflammatory pain models .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-18099
CAS No.: 878141-96-9
Synonyms: E-52862
Research Areas:  

Neurological Disease

S1RA (E-52862) is a highly selective σ1 receptor (σ1R) antagonist with Kis of 17 nM and 23.5 nM for human σ1R and guinea pig σ1R, respectively. S1RA has Moderate antagonistic activity for human 5-HT2B receptor (Ki= 328 nM). S1RA has antinociceptive effects in neuropathic pain models. S1RA prevents mechanical and cold hypersensitivity in Oxaliplatin (HY-17371)-treated mice .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-10413
CAS No.: 1006036-87-8
Purity:  99.31%
MK-2894 is a potent, selective, orally active and high affinity (Ki=0.56 nM) full antagonist against E prostanoid receptor 4 (EP4 receptor) (IC50=2.5 nM). MK-2894 possesses potent anti-inflammatory activity in animal models of pain/inflammation and can be used for the research of arthritis .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-11079
CAS No.: 944261-79-4
Purity:  99.09%
A-803467 is a potent and selective tetrodotoxin-resistant Nav1.8 sodium channel blocker (IC50=8 nM). A-803467 has shown significant anti-nociception in neuropathic and inflammatory pain models. A-803467 enhances the chemosensitivity of conventional anticancer agents through interaction with the ATP-binding cassette subfamily G member 2 (ABCG2) transporter .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-D0849
CAS No.: 305-53-3
Synonyms: Iodoacetic acid sodium salt
Sodium iodoacetate is a specific inhibitor of GAPDH and has glycolysis inhibitory activity. In addition, sodium iodoacetate can induce osteoarthritis and related pain models in experimental animals .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-15451
CAS No.: 1048973-47-2
Purity:  99.26%
Synonyms: BZO-HEXOXIZID
Target:  

Cannabinoid Receptor

Research Areas:  

Neurological Disease

MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a Ki of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-B0573A
CAS No.: 4199-10-4
(S)-(-)-Propranolol hydrochloride is the active isomer of Propranolol (HY-B0573B), with 98-fold greater activity than (R)-(+)-Propranolol. (S)-(-)-Propranolol hydrochloride produces antinociception-related phenotypes in mouse models, accompanied by sedative and ataxic side effects. (S)-(-)-Propranolol hydrochloride can be used in research related to hypertension, myocardial infarction, and pain .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-13954
CAS No.: 870061-27-1
Purity:  98.08%
A 839977 is a P2X7 selective antagonist; it blocks BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors (IC50 values are 20 nM, 42 nM and 150 nM respectively) and reduces inflammatory and neuropathic pain in animal models; the antihyperalgesic effects of P2X7 receptor blockade are mediated by blocking the release of IL-1beta .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-18618A
SB-612111 hydrochloride hydrochloride is a novel and potent opiate receptor-like orphan receptor (ORL-1) antagonist with a high affinity for hORL-1 (Ki=0.33 nM). SB-612111 hydrochloride exhibits selectivity for μ-,?κ- and?δ-receptors with Ki values of?57.6 nM, 160.5 nM and 2109 nM, respecticely. SB-612111 hydrochloride effectively antagonizes the pronociceptive action of Nociceptin (HY-P0183) in an acute pain model .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0745
CAS No.: 94596-28-8
Senkyunolide I is an orally active, blood-brain barrier-permeable metabolite of Z-ligustilide (HY-N0401A) . Senkyunolide I is isolated from Ligusticum chuanxiong. Senkyunolide I upregulates p-Erk1/2 and Nrf2/HO-1, and inhibits Caspase 3. Senkyunolide I alleviates Apoptosis. Senkyunolide I increases the pain threshold in mice and reduces acetic acid-induced writhing responses in mice. Senkyunolide I improves neurological deficits, reduces infarct volume and alleviates cerebral edema in rats with focal cerebral ischemia-reperfusion injury. Senkyunolide I protects renal function and structural integrity in a mouse model of renal ischemia-reperfusion injury. Senkyunolide I is applicable to research related to focal cerebral ischemia-reperfusion injury, migraine, and renal ischemia-reperfusion injury .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-120546
CAS No.: 1199236-64-0
Purity:  98.73%
Synonyms: Z944; PRAX-944
Ulixacaltamide (Z944) is an orally available T-type calcium channel antagonist that can slow the progression of epilepsy. Ulixacaltamide effectively reduces tremor in a normal alkaline tremor animal model. Ulixacaltamide reverses thermal hyperalgesia and mediates pain relief .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-106199
CAS No.: 40312-34-3
Purity:  98.93%
Adenosine A1 receptor activator T62 is an allosteric enhancer of adenosine A1 receptor. Adenosine A1 receptor activator T62 produces antinociception in animal models of acute pain and also reduces hypersensitivity in models of inflammatory and nerve-injury pain .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P10908
CAS No.: 3020015-02-2
Research Areas:  

Neurological Disease

H-20 is a PD-1 agonist peptide. H-20 increases μOR mRNA in DRG neurons and modulates μOR-mediated analgesia. H-20 produces synergistic analgesic effects in inflammatory pain models and can reduce analgesic-induced tolerance, hyperalgesia, constipation, and motor impairment. H-20 can be used in pain-related research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-133130
CAS No.: 1252765-13-1
Purity:  99.42%
Target:  

MAGL

Research Areas:  

Neurological Disease

JNJ-42226314, a chemical probe, is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-120380
CAS No.: 133314-07-5
Purity:  99.8%
Target:  

MOFs PARP

Research Areas:  

Neurological Disease

FeTMPyP is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. FeTMPyP inhibits cell death, nitrotyrosine formation, and depolarization of mitochondrial transmembrane potential. FeTMPyP reduces homocysteine-induced nitrosative stress and partially restores TFEB protein and mRNA levels. FeTMPyP improves functional and behavioral deficits caused by chronic constriction injury in rats. FeTMPyP alleviates acute cerebral infarction in a rat model of middle cerebral artery occlusion with mild hyperglycemia. FeTMPyP can be used in studies related to neuropathic pain, renal aging, ischemic penumbra, and hyperglycemic stroke .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0885
CAS No.: 472-26-4
Synonyms: Telobufotoxin; Telocinobufogenin
Telocinobufagin (Telobufotoxin; Telocinobufogenin) is an orally active bufadienolide with potential anti-tumor effects. Telocinobufagin exerts its anti-cancer effects on non-small cell carcinoma, osteosarcoma, thyroid cancer, breast cancer and head and neck squamous cell carcinoma by inhibiting the STAT3, JAK2/STAT3, LARP1-mTOR, PI3K/Akt/Snail and PLK1 pathways, and can also induce tumor cell apoptosis. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Telocinobufagin has a strong cardiac-stimulating effect by inhibiting the activity of Na +/K +-ATPase, and it can promote renal fibrosis. Telocinobufagin demonstrates non-opioid analgesic effects in various acute pain models .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N5084
CAS No.: 205370-59-8
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside is a TRPV1 antagonist and HDAC7 inhibitor. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside blocks TRPV1-mediated calcium influx, suppresses phosphorylation of p65, IκBα, p38, JNK, and ERK1/2, inhibiting NF-κB and MAPK signaling cascades. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside reduces production and gene expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside exhibits potent analgesic activity, elevates thermal pain threshold and mechanical pain threshold in murine models. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside restores CD8 + T cell infiltration into bladder cancer tumors and improves bladder cancer immunotherapy efficacy. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside can be used for the researches of painand bladder cancer .
loading...
    loading...
Cat. No.: HY-17444
CAS No.: 251565-85-2
Target:  

PPAR

Research Areas:  

Metabolic Disease Cancer

Tesaglitazar is a dual-target PPARα/γ agonist with an EC50 of 13.4 μM for rat PPARα and 3.6 μM for human PPARα. Tesaglitazar affects lipid and glucose metabolism by activating PPARα and PPARγ receptors, and has the potential to improve blood sugar and relieve pain. Tesaglitazar can be used to induce in vivo tumor models and can be used in the study of type 2 diabetes, dyslipidemia, and neuropathic pain .
loading...
    loading...
Cat. No.: HY-156815
CAS No.: 3077715-58-0
Purity:  99.96%
Target:  

Orphan GPCR

YL-365 is a potent and selective GPR34 antagonist with an IC50 of 17 nM. YL-365 binds to a portion of the orthosteric binding pocket of GPR34 and induces allosteric changes that stabilize the receptor in an inactive conformation. YL-365 down-regulates expression of the proinflammatory gene iNOS in M1 microglia and suppresses proinflammatory responses. YL-365 reduces mechanical allodynia in a dose-dependent manner in a mouse model of neuropathic pain. YL-365 can be used for the research of neuropathic pain .
loading...
    loading...